GPR55 and metabolic dysfunction-associated steatotic liver disease: If the LPI-GPR55 system can be consistently linked to liver injury, it will be exciting to test whether GPR55 antagonists can provide therapeutic benefit in ALD, NAFLD, or viral hepatitis.